In a closely watched development, the Second Circuit Court has granted Takeda Pharmaceuticals Co. the right to immediately appeal a decision by a New York federal judge that certified two classes of plaintiffs in ongoing antitrust litigation. The litigation includes claims from direct purchasers and end payors, who accuse the company of artificially inflating prices for its diabetes drug, Actos, by allegedly delaying the introduction of more affordable generic options. This legal maneuvering marks a significant juncture in the case, as the appeal challenges class certification, a critical milestone in antitrust cases.
Details of the proceedings and the implications for Takeda and the pharmaceutical industry are further elaborated in the original article on Law360.